Cross-platform transcriptomic profiling of the response to recombinant human erythropoietin

Guan Wang, Traci Kitaoka, Ali Crawford, Qian Mao, Andrew Hesketh, Fergus Guppy, Garrett I. Ash, Jason Liu, Mark Gerstein, Yannis Pitsiladis

Abstract: RNA-seq has matured into a vital tool for studying RNA biology. This study compared two RNA-seq platforms (MGI DNBSEQ and Illumina NextSeq 500) and two microarray platforms (GeneChip Human Transcriptome Array 2.0 and Illumina Expression BeadChip) in healthy individuals administered recombinant human erythropoietin (rHuEPO). The objective was to achieve transcriptome-wide quantification of differential gene expression. Results demonstrate that total RNA DNB-seq generated a significantly higher number of target genes compared to other platforms. Pathway enrichment analyses revealed that these genes correlate not only to erythropoiesis and oxygen transport but also to tissue protection and immune regulation. This research establishes a comprehensive knowledge base of genes relevant to EPO biology through rigorous cross-platform validation.

Introduction

Erythropoietin (EPO) is a primary hormone regulating red blood cell production. While its clinical use for treating anemia is well-established, its use as a performance-enhancing drug in sports necessitates sophisticated detection methods. Furthermore, the full scope of EPO's biological influence—particularly its non-erythropoietic effects on the immune system and tissue protection—remains partially understood. This study addresses these gaps by performing a head-to-head comparison of four modern transcriptomic technologies to map the human response to rHuEPO administration.

Methodology

The study involved 18 endurance-trained Caucasian males who received rHuEPO over several weeks. Blood samples were collected at eight time points (baseline, during treatment, and post-treatment). These samples were analyzed using four distinct platforms:

  1. MGI DNBSEQ-G400RS: Total RNA-sequencing.
  2. Illumina NextSeq 500: mRNA-sequencing.
  3. GeneChip HTA 2.0: Microarray.
  4. Illumina HumanHT-12 v4: Microarray.

A data triangulation approach was employed to identify biological signals that persisted across technologies, validated through Gene Set Enrichment Analysis (GSEA) and Reactome pathway analysis.

Results and Discussion

Superiority of Total RNA-Sequencing

The comparison revealed a stark difference in platform sensitivity. The MGI DNBSEQ platform, which sequences total RNA (including transcripts without poly-A tails), identified 1,552 differentially expressed genes (DEGs). In contrast, the Illumina mRNA-seq platform identified only 582 DEGs, and the microarray platforms were even less sensitive. At the peak response period (EPO4), approximately 66.8% of the genes identified were unique to the MGI platform.

Comparative heatmaps of differential gene expression across the four tested platforms (a-d), illustrating the varying levels of sensitivity and gene coverage.

Biological Insights: Beyond Erythropoiesis

The high sensitivity of the MGI platform allowed for the discovery of EPO’s roles in immune regulation and metabolic signaling. The data showed significant impacts on MHC class II antigen presentation and T-cell regulation, confirming EPO's function as a complex immune modulator. Additionally, gene sets related to mitophagy and mTOR signaling were identified, suggesting that EPO assists cells in managing oxidative stress and promoting survival.

Detailed heatmap of the MGI DNBSEQ transcriptomic profile, highlighting the extensive range of genes responsive to rHuEPO administration.

The 119-Gene Signature

Through cross-platform triangulation, the researchers identified a core signature of 119 high-confidence genes. This signature includes well-known erythropoietic targets such as ALAS2 and FECH, alongside novel immune-related targets. While RNA-seq platforms showed strong correlation (r = 0.74 to 0.85), the correlation with microarrays was significantly lower, indicating that microarrays may lack the resolution required for subtle physiological studies.

Conclusion

This study demonstrates that total RNA-sequencing (MGI DNBSEQ) provides the most comprehensive view of the transcriptomic response to rHuEPO. The identified 119-gene signature serves as a robust knowledge base for EPO biology and offers a potential framework for developing more effective anti-doping strategies, such as a transcriptomic "Biological Passport." Future research should aim to validate these findings in more diverse populations to ensure broader applicability.

Summary updated

Abstract

RNA-seq has matured and become an important tool for studying RNA biology. Here we compared two RNA-seq (MGI DNBSEQ and Illumina NextSeq 500) and two microarray platforms (GeneChip Human Transcriptome Array 2.0 and Illumina Expression BeadChip) in healthy individuals administered recombinant human erythropoietin for transcriptome-wide quantification of differential gene expression. The results show that total RNA DNB-seq generated a multitude of target genes compared to other platforms. Pathway enrichment analyses revealed genes correlate to not only erythropoiesis and oxygen transport but also a wide range of other functions, such as tissue protection and immune regulation. This study provides a knowledge base of genes relevant to EPO biology through cross-platform comparisons and validation.
BibTeX
@inproceedings{wang2021cross,
  author = {Guan Wang and Traci Kitaoka and Ali Crawford and Qian Mao and Andrew Hesketh and Fergus Guppy and Garrett I. Ash and Jason Liu and Mark Gerstein and Yannis Pitsiladis},
  title = {{Cross-platform transcriptomic profiling of the response to recombinant human erythropoietin}},
  booktitle = {Scientific},
  year = {2021},
  doi = {10.1038/s41598-021-00608-9},
}
Figure